Kasper DL - Search Results

1

Novel engagement of CD14 and multiple toll-like receptors by group B streptococci.

Henneke P, Takeuchi O, van Strijp JA, Guttormsen HK, Smith JA, Schromm AB, Espevik TA, Akira S, Nizet V, Kasper DL, Golenbock DT. Henneke P, et al. Among authors: kasper dl. J Immunol. 2001 Dec 15;167(12):7069-76. doi: 10.4049/jimmunol.167.12.7069. J Immunol. 2001. PMID: 11739528

2

Quantitative determination of antibodies to type III group B streptococcal polysaccharide.

Guttormsen HK, Baker CJ, Edwards MS, Paoletti LC, Kasper DL. Guttormsen HK, et al. Among authors: kasper dl. J Infect Dis. 1996 Jan;173(1):142-50. doi: 10.1093/infdis/173.1.142. J Infect Dis. 1996. PMID: 8537651

3

Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.

Kasper DL, Paoletti LC, Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ. Kasper DL, et al. J Clin Invest. 1996 Nov 15;98(10):2308-14. doi: 10.1172/JCI119042. J Clin Invest. 1996. PMID: 8941648 Free PMC article. Clinical Trial.

4

Immunologic memory induced by a glycoconjugate vaccine in a murine adoptive lymphocyte transfer model.

Guttormsen HK, Wetzler LM, Finberg RW, Kasper DL. Guttormsen HK, et al. Among authors: kasper dl. Infect Immun. 1998 May;66(5):2026-32. doi: 10.1128/IAI.66.5.2026-2032.1998. Infect Immun. 1998. PMID: 9573085 Free PMC article.

5

Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.

Wessels MR, Paoletti LC, Guttormsen HK, Michon F, D'Ambra AJ, Kasper DL. Wessels MR, et al. Among authors: kasper dl. Infect Immun. 1998 May;66(5):2186-92. doi: 10.1128/IAI.66.5.2186-2192.1998. Infect Immun. 1998. PMID: 9573106 Free PMC article.

6

Cellular mechanism of intraabdominal abscess formation by Bacteroides fragilis.

Gibson FC 3rd, Onderdonk AB, Kasper DL, Tzianabos AO. Gibson FC 3rd, et al. Among authors: kasper dl. J Immunol. 1998 May 15;160(10):5000-6. J Immunol. 1998. PMID: 9590249

7

Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.

Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME, Kasper DL. Baker CJ, et al. Among authors: kasper dl. J Infect Dis. 1999 Jan;179(1):142-50. doi: 10.1086/314574. J Infect Dis. 1999. PMID: 9841833 Clinical Trial.

8

Mitogenic activity of purified capsular polysaccharide A from Bacteroides fragilis: differential stimulatory effect on mouse and rat lymphocytes in vitro.

Brubaker JO, Li Q, Tzianabos AO, Kasper DL, Finberg RW. Brubaker JO, et al. Among authors: kasper dl. J Immunol. 1999 Feb 15;162(4):2235-42. J Immunol. 1999. PMID: 9973499

9

IL-2 mediates protection against abscess formation in an experimental model of sepsis.

Tzianabos AO, Russell PR, Onderdonk AB, Gibson FC 3rd, Cywes C, Chan M, Finberg RW, Kasper DL. Tzianabos AO, et al. Among authors: kasper dl. J Immunol. 1999 Jul 15;163(2):893-7. J Immunol. 1999. PMID: 10395684

10

Measurement of human antibodies to type III group B Streptococcus.

Kasper DL, Wessels MR, Guttormsen HK, Paoletti LC, Edwards MS, Baker CJ. Kasper DL, et al. Infect Immun. 1999 Aug;67(8):4303-5. doi: 10.1128/IAI.67.8.4303-4305.1999. Infect Immun. 1999. PMID: 10447392 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

354 results

Search Page

Filters